When a company such as Synaptogenix conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the SNPX split history from start to finish, an original position size of 1000 shares would have turned into 40 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Synaptogenix shares, starting with a $10,000 purchase of SNPX, presented on a split-history-adjusted basis factoring in the complete SNPX split history.

About Synaptogenix

Synaptogenix is a biopharmaceutical company. Co. is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. Co. is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing. Co. has completed an additional analysis in connection with the confirmatory Phase 2 study, which examined moderately severe to severe AD patients treated with Bryostatin-1 in the absence of memantine. According to our SNPX split history records, Synaptogenix has had 1 split.

SNPX Split History | www.SplitHistory.com | Copyright © 2013 - 2025, All Rights Reserved